西格列他/二甲双胍缓释片食物影响及多次给药研究
评估西格列他/二甲双胍缓释固定剂量复方片食物效应及多剂量药代动力学的I期临床研究
This trial includes two parts: a food effect (FE) study and a multiple-dose pharmacokinetic (PK) study.
The FE study is a randomized, open-label, two-period, two-sequence crossover study designed to evaluate the effect of a high-fat meal on the PK of a single oral dose of Chiglitazar/Metformin extended-release tablets in healthy adult Chinese participants.
The multiple-dose PK study is an open-label study designed to evaluate the PK characteristics of Chiglitazar/Metformin extended-release tablets in healthy adult Chinese participants following multiple oral doses.
研究概览
地位
条件
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、101300
- Beijing Ditan Hospital, Capital Medical University
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Healthy male or female participants;
- Age from 18 to 45 years, inclusive;
- Body Mass Index (BMI) between 19.0 and 26.0 kg/m² (inclusive). Male participants must weigh at least 50.0 kg, and female participants must weigh at least 45.0 kg;
- From the time of signing the informed consent form until 3 months after the last dose, participants must have no plans for pregnancy or sperm donation and must be willing to use effective contraceptive measures;
- Voluntarily agrees to participate in the study and signs the informed consent form.
Exclusion Criteria:
- Any clinically significant abnormalities in laboratory tests or a history of clinically significant diseases, including but not limited to cardiovascular, cerebrovascular, hepatic, renal, respiratory, gastrointestinal, neurological, hematological, immune, oncological, psychiatric, or endocrine/metabolic disorders;
- Known history of severe allergies (e.g., allergy to more than 3 allergens, allergies affecting the lower respiratory tract such as allergic asthma, allergies requiring glucocorticoid treatment) or a known history of allergy to any component of the investigational products;
- Previous surgery that could affect drug absorption, distribution, metabolism, or excretion (e.g., subtotal gastrectomy), or a history of gastrointestinal, hepatic, or renal disease within the last 6 months that could affect drug absorption or metabolism;
- Surgery within 3 months prior to screening or planned surgery during the study period;
- Received any vaccination within 1 month prior to screening or plan to receive any vaccination during the study period;
- History of infectious disease treated with significant use of antibiotics within 3 months before the first dose, or any infectious disease within 7 days before the first dose;
- Presence of gastrointestinal symptoms (e.g., diarrhea, constipation, nausea, vomiting) within 7 days before the first dose, which the investigator deems unsuitable for study participation;
- Use of any prescription drugs, over-the-counter drugs, or Chinese herbal medicines within 1 month before the first dose; or use of vitamin products within 2 weeks before enrollment;
- History of drug or substance abuse, or a positive alcohol or urine drug screening test;
- Intolerance to venipuncture, or a history of fainting in response to needles or blood;
- Fasting blood glucose > 6.1 mmol/L or < 3.9 mmol/L at screening, and/or a history of hypoglycemia/syncope;
- Participation in any interventional clinical trial within 3 months prior to screening;
- Blood donation or significant blood loss (> 200 mL) within 3 months prior to screening;
- Pregnant or lactating women;
- Weekly alcohol consumption of more than 14 units within 3 months prior to screening, consumption of alcohol within 48 hours before the first dose, or inability to abstain from alcohol during the study;
- Smokes more than 5 cigarettes per day within 3 months prior to screening, has smoked within 48 hours before the first dose, or is unable to abstain from smoking during the study;
- Excessive daily consumption of tea, coffee, and/or caffeinated beverages within 3 months prior to screening, or consumption of such beverages within 48 hours before the first dose;
- Consumption of grapefruit or grapefruit-related citrus fruits (e.g., Seville oranges, pomelos), star fruit, papaya, pomegranate, or their products within 14 days before the first dose;
- Glomerular Filtration Rate (GFR) < 90 mL/min/1.73 m²;
- Systolic blood pressure < 90 mmHg or ≥ 140 mmHg, or diastolic blood pressure < 50 mmHg or ≥ 90 mmHg at screening;
- Inability to comply with the standardized diet (e.g., intolerance to the high-fat meal, lactose intolerance) or has difficulty swallowing;
- Plans to or is required to engage in strenuous physical activity or exercise during the study period;
- Any other condition that, in the opinion of the investigator, makes the participant unsuitable for inclusion in the study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:FE研究序列1
|
a single dose of Chiglitazar/Metformin extended-release tablets under fasting conditions a single dose of Chiglitazar/Metformin extended-release tablets after a high-fat meal |
|
实验性的:FE研究第2序列
|
a single dose of Chiglitazar/Metformin extended-release tablets under fasting conditions a single dose of Chiglitazar/Metformin extended-release tablets after a high-fat meal |
|
实验性的:多剂量组
|
a single dose on Day 1, once-daily consecutive doses from Day 4 to Day 10 |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
FE研究:最大血浆浓度(Cmax)
大体时间:给药前及给药后72小时内多个时间点
|
给药前及给药后72小时内多个时间点
|
|
FE研究:血浆浓度-时间曲线下面积(AUC)
大体时间:给药前及给药后多个时间点(最长72小时)
|
给药前及给药后多个时间点(最长72小时)
|
|
FE研究:达峰时间(Tmax)
大体时间:给药前以及给药后72小时内的多个时间点
|
给药前以及给药后72小时内的多个时间点
|
|
FE研究:消除半衰期(t1/2)
大体时间:给药前以及给药后72小时内多个时间点
|
给药前以及给药后72小时内多个时间点
|
|
FE 研究:表观总清除率 (CL/F)
大体时间:给药前以及给药后72小时内多个时间点
|
给药前以及给药后72小时内多个时间点
|
|
FE研究:终末期的表观分布容积(Vz/F)
大体时间:给药前及给药后至72小时内的多个时间点
|
给药前及给药后至72小时内的多个时间点
|
|
多次给药药代动力学研究:最大血浆浓度(Cmax)
大体时间:给药前至末次给药后72小时(连续给药7天)
|
给药前至末次给药后72小时(连续给药7天)
|
|
多剂量药代动力学研究:血浆浓度-时间曲线下面积(AUC)
大体时间:末次给药前至给药后72小时(连续给药7天)
|
末次给药前至给药后72小时(连续给药7天)
|
|
多次给药药代动力学研究:达峰时间(Tmax)
大体时间:末次给药前至末次给药后72小时(连续给药7天)
|
末次给药前至末次给药后72小时(连续给药7天)
|
|
多次给药药代动力学研究:稳态峰值浓度(Cmax,ss)
大体时间:末次给药前至给药后72小时(连续7天给药)
|
末次给药前至给药后72小时(连续7天给药)
|
|
多剂量药代动力学研究:稳态达峰时间(Tmax,ss)
大体时间:末次给药前至末次给药后72小时(连续给药7天)
|
末次给药前至末次给药后72小时(连续给药7天)
|
|
多次给药药代动力学研究:稳态血浆浓度-时间曲线下面积(AUCss)
大体时间:末次给药前至给药后72小时(连续给药7天)
|
末次给药前至给药后72小时(连续给药7天)
|
|
多剂量药代动力学研究:谷浓度
大体时间:末次给药前至给药后72小时(连续给药7天)
|
末次给药前至给药后72小时(连续给药7天)
|
|
多剂量药代动力学研究:蓄积比 (Rac)
大体时间:末次给药前至给药后72小时(连续给药7天)
|
末次给药前至给药后72小时(连续给药7天)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
不良事件(AEs)发生率
大体时间:最多 16 天
|
最多 16 天
|
|
|
Change from baseline in hematology parameters: white blood cell count, neutrophil count, lymphocyte count, monocyte count, eosinophil count, basophil count, red blood cell count , hemoglobin, hematocrit, platelet count
大体时间:up to Day 13
|
Change from baseline in hematology parameters: white blood cell count (WBC), neutrophil count, lymphocyte count, monocyte count, eosinophil count, basophil count, red blood cell count (RBC), hemoglobin (Hb), hematocrit (HCT), platelet count (PLT) |
up to Day 13
|
|
Changes from baseline in serum chemistry parameters
大体时间:up to Day 13
|
Changes from baseline in serum chemistry parameters: fasting blood glucose (FBG), total protein, albumin, total bilirubin, direct bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), blood urea nitrogen (BUN) or urea, uric acid, creatinine, potassium (K⁺), sodium (Na⁺), chloride (Cl-), creatine kinase (CK) |
up to Day 13
|
|
Changes from baseline in urinalysis parameters: urine protein, urine ketones, urine glucose, urine pH, urine leukocytes, urine red blood cells
大体时间:up to Day 13
|
Changes from baseline in urinalysis parameters: urine protein, urine ketones, urine glucose, urine pH, urine leukocytes, urine red blood cells (RBCs) |
up to Day 13
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.